- BB BIOTECH: Initiation of 6th share buyback on September 16, 2009
- Incyte: Positive Phase II results for its lead JAK inhibitor in patients with mild-to-moderate psoriasis
- Arena: 2nd Phase III study confirms efficacy and safety of Lorcaserin